Book 2007

evaluating clinical research

All that glitters is not gold


ISBN: 978-0-387-72898-8 (Print) 978-0-387-72899-5 (Online)

Table of contents (26 chapters)

previous Page of 2
  1. Front Matter

    Pages I-IV

  2. Chapter

    Pages 1-3

    What is the purpose of this book?

  3. Chapter

    Pages 5-10

    Why is benefit-to-harm balance essential to treatment decisions?

  4. Chapter

    Pages 11-16

    What are the strengths of randomized controlled clinical trials?

  5. Chapter

    Pages 17-22

    What are the weaknesses of randomized controlled clinical trials?

  6. Chapter

    Pages 23-28

    Do meta-analyses provide the ultimate truth?

  7. Chapter

    Pages 29-34

    What are the strengths of observational studies?

  8. Chapter

    Pages 35-37

    What are the weaknesses of observational studies?

  9. Chapter

    Pages 39-43

    Were the scientific questions stated in advance?

  10. Chapter

    Pages 45-48

    Were the treatment groups comparable initially?

  11. Chapter

    Pages 49-52

    Why is blinding/masking so important?

  12. Chapter

    Pages 53-56

    How is symptomatic improvement measured?

  13. Chapter

    Pages 57-60

    Is it really possible to assess quality of life?

  14. Chapter

    Pages 61-65

    What is the value of biologic markers in drug evaluation?

  15. Chapter

    Pages 67-71

    How are adverse drug reactions measured?

  16. Chapter

    Pages 73-76

    How representative are study subjects in clinical trials?

  17. Chapter

    Pages 77-81

    What happened to the study subjects who disappeared from the analysis?

  18. Chapter

    Pages 83-88

    How reliable are active-control trials?

  19. Chapter

    Pages 89-93

    How informative are composite outcomes?

  20. Chapter

    Pages 95-98

    Do changes in biologic markers predict clinical benefit?

  21. Chapter

    Pages 99-102

    How trustworthy are the authors?

previous Page of 2